Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated just now
Peer-reviewedCC BY 4.0Trials

Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor: the Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)—study protocol for a phase IV randomized controlled trial

5 more authors

Abstract

Background: Significant interindividual variability in tumor necrosis factor inhibitor (TNFi) drug levels and anti-drug antibody formation contribute to treatment failure and disease flares in rheumatoid arthritis (RA). Proactive therapeutic drug monitoring (TDM), individualized drug dosing based on regular assessments of serum drug levels and anti-drug antibodies (ADAb), may improve TNFi therapy. However, evidence regarding the use of TDM in subcutaneous (SC) TNFi treatment is lacking. This study evaluates whether a treatment strategy incorporating TDM is superior to standard of care in maintaining sustained disease control without flares in RA patients treated with SC TNFi (adalimumab).

Methods: RA-DRUM is a multicenter, multinational, randomized, two-arm, parallel-group, open superiority trial. Adult participants with RA in remission or low disease activity on therapy with standard dose of a SC TNFi (adalimumab) for 3–24 months with indication for continuation of treatment are allocated to administration of TNFi based on proactive TDM (TDM group) or administration of TNFi based on standard of care without knowledge of drug or ADAb levels (standard of care group). In the TDM group, dosing will be adjusted with the aim of keeping the serum adalimumab 5.0–12.0 mg/L. The primary endpoint is sustained disease control without flare over the 18 months follow-up period.

Discussion: TNFi is a cornerstone in the treatment of RA and other immune-mediated inflammatory diseases, and there is a strong rationale to achieve the best possible results of the drug. TDM has been suggested as a strategy to improve treatment with TNFi therapy. This randomized trial comparing TDM to standard of care for maintaining sustained disease control will fill a clinically important knowledge gap of high relevance for the management of a common disease with a potentially disabling disease course.

Trial registration: EU CT No: 2023-510184-35-00, registered on January 31st, 2024. ClinicalTrials.gov NCT06440629, registered on May 23th, 2024, https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-510184-35-00 .

Related

  1. Alkaline Phosphatases: A Potential Cause of Variability in Therapeutic Response to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion?
    Manon Auffret, Marc Vérin
    Movement DisordersPeer-reviewedCC BY-NC-ND 4.0Full text2 citedNeurologyHAL
  2. Targeting the NLRP3 inflammasome in rheumatoid arthritis fibroblast-like synoviocytes: pathogenic mechanisms, therapeutic strategies, and translational perspectives
    Lunmin Bao, Haibing Dai, Daoming Wang +1
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  3. Deciphering the Therapeutic Effect of Quercetin-Loaded Pumpkin Seed Oil Nanoemulsion on Rheumatoid Arthritis in a Rat Model
    Hanan Hendawy, Mohamed Korish, Nourhan Gamal El-Rahmany +4
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Research progress of mitophagy and its targeted therapeutic strategies in rheumatoid arthritis
    Yuanyuan Zhang, Fengmei Ge, Xuebin Wang
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMCEurope PMCPMC
  5. Computational Prediction of the Therapeutic Mechanisms From the Turmeric-Pueraria-Coix Seed Botanical Formula in Rheumatoid Arthritis.
    Weiya Lan, Qianwei Lu, Xudong Rui +7
    Food science & nutritionPeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{jyssum2026effect,
  title = {{Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor: the Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)—study protocol for a phase IV randomized controlled trial}},
  author = {Ingrid Jyssum and Johanna E. Gehin and Joseph Sexton and Guro L. Goll and Camilla Skancke Mørstad and Eirik K. Kristianslund and Marthe K. Brun and Helga Lechner-Radner and Daniel Aletaha and Katerina Chatzidionysiou and Catalin Codreanu and Costantino Pitzalis and Michele Bombardieri and Siri Lillegraven and Nils Bolstad and Espen A. Haavardsholm and Silje W. Syversen},
  journal = {Trials},
  year = {2026},
  month = nov,
  doi = {10.1186/s13063-026-10090-1},
  url = {https://link.springer.com/article/10.1186/s13063-026-10090-1},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor: the Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)—study protocol for a phase IV randomized controlled trial
AU  - Ingrid Jyssum
AU  - Johanna E. Gehin
AU  - Joseph Sexton
AU  - Guro L. Goll
AU  - Camilla Skancke Mørstad
AU  - Eirik K. Kristianslund
AU  - Marthe K. Brun
AU  - Helga Lechner-Radner
AU  - Daniel Aletaha
AU  - Katerina Chatzidionysiou
AU  - Catalin Codreanu
AU  - Costantino Pitzalis
AU  - Michele Bombardieri
AU  - Siri Lillegraven
AU  - Nils Bolstad
AU  - Espen A. Haavardsholm
AU  - Silje W. Syversen
PY  - 2026
DA  - 2026/11/14
JO  - Trials
DO  - 10.1186/s13063-026-10090-1
UR  - https://link.springer.com/article/10.1186/s13063-026-10090-1
AB  - Background: Significant interindividual variability in tumor necrosis factor inhibitor (TNFi) drug levels and anti-drug antibody formation contribute to treatment failure and disease flares in rheumatoid arthritis (RA). Proactive therapeutic drug monitoring (TDM), individualized drug dosing based on regular assessments of serum drug levels and anti-drug antibodies (ADAb), may improve TNFi therapy. However, evidence regarding the use of TDM in subcutaneous (SC) TNFi treatment is lacking. This study evaluates whether a treatment strategy incorporating TDM is superior to standard of care in maintaining sustained disease control without flares in RA patients treated with SC TNFi (adalimumab).  Methods: RA-DRUM is a multicenter, multinational, randomized, two-arm, parallel-group, open superiority trial. Adult participants with RA in remission or low disease activity on therapy with standard dose of a SC TNFi (adalimumab) for 3–24 months with indication for continuation of treatment are allocated to administration of TNFi based on proactive TDM (TDM group) or administration of TNFi based on standard of care without knowledge of drug or ADAb levels (standard of care group). In the TDM group, dosing will be adjusted with the aim of keeping the serum adalimumab 5.0–12.0 mg/L. The primary endpoint is sustained disease control without flare over the 18 months follow-up period.  Discussion: TNFi is a cornerstone in the treatment of RA and other immune-mediated inflammatory diseases, and there is a strong rationale to achieve the best possible results of the drug. TDM has been suggested as a strategy to improve treatment with TNFi therapy. This randomized trial comparing TDM to standard of care for maintaining sustained disease control will fill a clinically important knowledge gap of high relevance for the management of a common disease with a potentially disabling disease course.  Trial registration: EU CT No: 2023-510184-35-00, registered on January 31st, 2024. ClinicalTrials.gov NCT06440629, registered on May 23th, 2024, https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-510184-35-00 .
SN  - 1745-6215
ER  -